Publications by authors named "Jidapa Triwatcharikorn"

Objective: Botulinum toxin injection is a well-established treatment for primary hyperhidrosis. The botulinum toxin-loaded detachable dissolvable microneedles (BoNT-MNs) were developed in a result of disadvantages of the intradermal procedure. This pilot study aims to evaluate the efficacy and safety of BoNT-MNs.

View Article and Find Full Text PDF
Article Synopsis
  • Thirty-one participants (mean age 38.35 years, mostly male) were monitored for skin conditions at multiple intervals post-surgery, with common issues including striae, acanthosis nigricans, and plantar hyperkeratosis being observed.
  • While BaS led to improvements in various skin issues, it also resulted in acute telogen effluvium in over half of the patients, with some skin biophysical properties remaining unchanged, except for decreased facial sebum production and reduced elasticity over time.
View Article and Find Full Text PDF

Background: At present, no predictive models are available to determine the probability of in-hospital mortality rates (HMRs) in all phenotypes of severe cutaneous adverse reactions (SCARs).

Objectives: Our study explored whether simple clinical and laboratory assessments could help predict the HMRs in any phenotypes of SCAR patients.

Methods: Factors influencing HMRs in 195 adults diagnosed with different SCAR phenotypes were identified, and their optimal cut-offs were determined by Youden's index.

View Article and Find Full Text PDF

Clinical applications of skin testing are known to help diagnose IgE-mediated and T-cell-mediated delayed cutaneous reactions. By contrast, drug-induced immune complex-mediated vasculitis is primarily diagnosed based on medical history, clinical setting and laboratory evidence of immune-complex formation, as there are no proven methods to identify the suspect culprit. We report three cases of drug- or biologic-induced immune complex-mediated vasculitis, in which the culprit agents could be confirmed by a positive intradermal test with later reading (between 12 and 24 h after the test), with verification by immunohistochemical or immunofluorescent results.

View Article and Find Full Text PDF

Urticaria is a common cutaneous adverse event from coronavirus disease 2019 vaccination. Previous studies hypothesized that excipients as polyethylene glycol in BNT162b2 vaccine and polysorbate in ChAdOx1 nCoV-19 vaccine are allergens. A 28-year-old woman had urticaria after a booster vaccination with BNT162b2 at the site of previous intradermal injection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein.

View Article and Find Full Text PDF